Biotech

Angle PLC: Cancer Research UK Contract

GUILDFORD, SURREY: ...

Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to ''Usual Care''

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA: Pioneering GSK Study Provides Important New Data on the Effectiveness of Relvar Ellipta (FF/VI) When Used in Everyday Clinical Practice ...

Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences

TUSTIN, CA: Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise ...

Vaxil Board Member Joins Ontario Premier Kathleen Wynne''s Business Mission to Israel

TORONTO, ONTARIO and REHOVOT, ISRAEL: ...

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting

TORONTO, ONTARIO: ...

GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in Patients With COPD at ATS Conference

SOUTH SAN FRANCISCO, CA: ...

Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update

EDMONTON, ALBERTA: Ceapro Posts Highest Quarterly Revenues Reported in Company's History Expected Commencement of Clinical Program With Avenanthramides as Anti-Inflammatory Compound Before Year End Pilot Clinical S ...

Bingo to Biotech: the Pharma-Bio Industry Breathes New Life Into Old Buildings Across the World, an Industrial Info News Alert

SUGAR LAND, TX: ...

New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA

DUBLIN, IRELAND: Presentation at American Thoracic Society 2016 International Conference Suggests Potential Efficacy and Overall Mortality Benefits for Select HABP/VABP Patients With VIBATIV Therapy; Shows No Statisti ...

Microbix Revenue Grows 7% in Second Quarter

TORONTO, ONTARIO: Company provides corporate updates ...